^
Association details:
| Biomarker: | ATM mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | alrizomadlin (APG-115) (MDM2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Excerpt:
...Cohort C: Histologically confirmed, unresectable or metastatic solid tumors with P53WT and ATM mutation (including germline ATM mutation) 6....
Trial ID:
Source:
Title:
Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.
Published date:
05/28/2021
Excerpt:
...ATM mutant solid tumors that had failed any standard therapy...Alrizomadlin combined with pembrolizumab is well tolerated and may restore antitumor effects in pts with cancer resistant to or intolerant of I-O drugs, as suggested by preliminary antitumor activities in multiple tumor types.
DOI:
10.1200/JCO.2021.39.15_suppl.2506
Trial ID:
